PT1021196E - Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio - Google Patents
Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenioInfo
- Publication number
- PT1021196E PT1021196E PT98946681T PT98946681T PT1021196E PT 1021196 E PT1021196 E PT 1021196E PT 98946681 T PT98946681 T PT 98946681T PT 98946681 T PT98946681 T PT 98946681T PT 1021196 E PT1021196 E PT 1021196E
- Authority
- PT
- Portugal
- Prior art keywords
- antigen
- inhibit
- chloride solution
- response specific
- treating
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 229910001919 chlorite Inorganic materials 0.000 abstract 3
- 229910052619 chlorite group Inorganic materials 0.000 abstract 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6095397P | 1997-10-06 | 1997-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1021196E true PT1021196E (pt) | 2004-06-30 |
Family
ID=22032774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98946681T PT1021196E (pt) | 1997-10-06 | 1998-10-06 | Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20050129784A1 (enExample) |
| EP (1) | EP1021196B1 (enExample) |
| JP (1) | JP4369615B2 (enExample) |
| CN (1) | CN1152691C (enExample) |
| AT (1) | ATE258799T1 (enExample) |
| AU (1) | AU754928B2 (enExample) |
| CA (1) | CA2306273A1 (enExample) |
| DE (1) | DE69821506T2 (enExample) |
| DK (1) | DK1021196T3 (enExample) |
| ES (1) | ES2217582T3 (enExample) |
| PT (1) | PT1021196E (enExample) |
| WO (1) | WO1999017787A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148189A0 (en) * | 1999-08-18 | 2002-09-12 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
| AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8067035B2 (en) | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| EA201290041A1 (ru) * | 2009-08-06 | 2012-07-30 | Ньюралтус Фармасьютикалс, Инк. | Лечение расстройств, связанных с макрофагами |
| US9266957B2 (en) | 2009-11-10 | 2016-02-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating renal cell carcinoma and glioblastoma multiforme |
| RU2014130080A (ru) | 2011-12-22 | 2016-02-10 | Нуво Рисерч Гмбх | Липосомальные композиции хлоритов или хлоратов |
| CN104519890A (zh) * | 2012-01-19 | 2015-04-15 | Ibt美国公司 | 四氯十氧(tcdo)的治疗应用 |
| WO2014078272A1 (en) | 2012-11-13 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
| US10094835B2 (en) | 2013-05-09 | 2018-10-09 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
| US11813234B2 (en) | 2015-08-20 | 2023-11-14 | Oxo Translational Science Gmbh | Use of chlorite to treat red blood cell diseases and indications mediated thereby |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| DE3515745A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
| DE3515749A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden |
| US4851222A (en) * | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
| US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
| DE4208828A1 (de) * | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen |
| US5830511A (en) * | 1992-06-25 | 1998-11-03 | Bioxy Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
| US5877222A (en) * | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
-
1998
- 1998-10-06 AU AU93642/98A patent/AU754928B2/en not_active Ceased
- 1998-10-06 EP EP98946681A patent/EP1021196B1/en not_active Expired - Lifetime
- 1998-10-06 AT AT98946681T patent/ATE258799T1/de active
- 1998-10-06 JP JP2000514658A patent/JP4369615B2/ja not_active Expired - Fee Related
- 1998-10-06 PT PT98946681T patent/PT1021196E/pt unknown
- 1998-10-06 CN CNB988118858A patent/CN1152691C/zh not_active Expired - Fee Related
- 1998-10-06 WO PCT/IB1998/001676 patent/WO1999017787A2/en not_active Ceased
- 1998-10-06 ES ES98946681T patent/ES2217582T3/es not_active Expired - Lifetime
- 1998-10-06 DE DE69821506T patent/DE69821506T2/de not_active Expired - Lifetime
- 1998-10-06 DK DK98946681T patent/DK1021196T3/da active
- 1998-10-06 CA CA002306273A patent/CA2306273A1/en not_active Abandoned
-
2004
- 2004-07-22 US US10/895,941 patent/US20050129784A1/en not_active Abandoned
-
2008
- 2008-06-04 US US12/132,761 patent/US20090004295A1/en not_active Abandoned
-
2010
- 2010-09-30 US US12/894,618 patent/US20110076344A1/en not_active Abandoned
-
2012
- 2012-02-06 US US13/366,595 patent/US20120141514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU754928B2 (en) | 2002-11-28 |
| EP1021196A2 (en) | 2000-07-26 |
| US20120141514A1 (en) | 2012-06-07 |
| DE69821506T2 (de) | 2004-12-16 |
| CN1306433A (zh) | 2001-08-01 |
| WO1999017787A3 (en) | 1999-06-17 |
| CN1152691C (zh) | 2004-06-09 |
| DE69821506D1 (de) | 2004-03-11 |
| CA2306273A1 (en) | 1999-04-15 |
| EP1021196B1 (en) | 2004-02-04 |
| US20110076344A1 (en) | 2011-03-31 |
| ATE258799T1 (de) | 2004-02-15 |
| AU9364298A (en) | 1999-04-27 |
| ES2217582T3 (es) | 2004-11-01 |
| JP4369615B2 (ja) | 2009-11-25 |
| JP2001518512A (ja) | 2001-10-16 |
| WO1999017787A2 (en) | 1999-04-15 |
| DK1021196T3 (da) | 2004-06-07 |
| US20090004295A1 (en) | 2009-01-01 |
| US20050129784A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bloom et al. | Selective primary health care: strategies for control of disease in the developing world. V. Leprosy | |
| Schwab et al. | Association of experimental chronic arthritis with the persistence of group A streptococcal cell walls in the articular tissue | |
| DE69939747D1 (de) | Verfahren von dna-impfung | |
| ATE228373T1 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
| FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
| IL132468A0 (en) | A kit for inducing immune response against a tumor or a disease caused by an infection agent | |
| AU7980794A (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
| LV12085A (lv) | Dendritiskas sunas stimulejosais faktors | |
| DE69329344D1 (de) | Spezifische modulationen des immunsystems | |
| CY1106400T1 (el) | Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο | |
| DK0769020T3 (da) | Nye hIL-4-mutantproteiner som antagonister eller delvise agonister for det humane interleukin-4 | |
| DK1021196T3 (da) | Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion | |
| DE69110877D1 (de) | Idiotypen-impfung gegen b-zell-lymphoma. | |
| Demengeot et al. | Regulatory T cells in microbial infection | |
| RU94045825A (ru) | Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство | |
| Undeen et al. | Nosema algerae: infection of the white mouse by a mosquito parasite | |
| Brown | Molecular approaches to elucidating innate and acquired immune responses to Babesia bovis, a protozoan parasite that causes persistent infection | |
| Burns et al. | Immunology and infectious disease | |
| Levitt et al. | The immunobiology of Chlamydia | |
| Mehra et al. | Induction of cell-mediated immunity to Mycobacterium leprae in guinea pigs | |
| YU40796A (sh) | Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije | |
| HUP9800613A2 (hu) | Humán Fas-antigén elleni humanizált antitest | |
| ATE164311T1 (de) | Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten | |
| Raffel | Bacterial hypersensitivity | |
| Sabolovic et al. | Effect of a protein bound polysaccharide (PS-K) on tumor development and infections in splenectomized rats and mice |